Follow the SK바이오사이언스 share price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Technology sector, SK바이오사이언스 has published 68 public disclosures. Market capitalisation: €1,362,211.6bn. The latest transaction was filed on 24 February 2026 (Purchase). Among the most active insiders: 김훈. Every trade is free.
68
Insider Decl.
n/a
Thresholds
n/a
57 ops.
Buy Volume
n/a
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate SK바이오사이언스 Strong Buy (bullish), based on 37 analysts. Average price target: ₩3,408,502.
2Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,781 of 29,063 companies
66.9
score / 100
Value
45
Quality
89
FCF yld2.1%
Earn yld3.7%
EV/EBITDA18.3x
ROE93%
Gross mgn60%
Net mgn44%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
